Hepatitis C-related liver diseases continue to kill an estimated 15,000 people per year in the United States, despite the availability of an effective cure.
This publication explores the role of community engagement in health-related research and development (R&D), particularly within the Unitaid-funded LONGEVITY Project.
Following the White House’s recent proposal for a National Hepatitis C Elimination Plan as part of its Fiscal Year 2024 budget request to Congress, and the fact that key populations for HIV are also at high risk of HCV, Treatment Action Group is organizing a webinar that will highlight best practices and challenges for HCV elimination with a specific focus on high-burden populations.
Treatment Action Group welcomes the inclusion of Ravidasvir on the World Health Organization (WHO) Essential Medicines List (EML) as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection in adults.
This policy brief explores barriers such as the high-burden among marginalized communities, the complicated diagnostic process, and the difficulties of finding the missing millions of people with HCV in most high-burden countries.
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
On November 16, 2022, please join TAG, INPUD and AfroCAB for our webinar “Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies” at 8:00 a.m. EST / 02:00 p.m. CET / 05:30 IST.